skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

ファーマインテリジェンスが選ばれる理由

business Intelligence sales forecasts pharma intelligence

世界有数の医薬品業界情報プロバイダー

日々激しさを増す医薬品・医療機器市場において、質の高い医薬品業界ニュースやマーケット分析をグローバルで提供する世界有数の情報プロバイダーです。

news and insight analyst page expertise in all areas pharma intelligence

リアルタイムのニュース配信サービス

世界中のアナリストがリアルタイムの医薬品業界ニュースを毎日配信します。事実の報道だけでなく、グローバルな視点で独自の分析と見解をご提供します。

data and analysis indepth company profiles pharma intelligence

確固たるデータに基づいた分析

当社が提供する分析は、175か国、4万2千社による24万8千件の臨床試験、および、1400種の疾病に対する6万5千の医薬品データに基づいています。

consultancies pharma intelligence

オーダーメードのプロジェクトもご提供

顧客企業ごとのビジネスニーズに対応する実用的なコンサルテーションサービスをご提供します。投資利益率向上のためにお客様の組織を内側から支えます。

ask the analyst pharma intelligence

世界規模の視点が強み医薬専門のアナリスト

300名超の専属アナリストと65名のジャーナリストが、世界中の製薬業界情報を網羅します。

dedicated account manager pharma intelligence

3000社以上のお客様と取引実績

当社は世界の製薬会社トップ50社および医薬品開発業務受託機関(CRO)の上位10社を含む3000社以上のお客様にサービスをご提供してきました。

 

gold standard service product developments pharma intelligence

顧客第一のカスタマーサポート

ニュース配信サービスから調査・分析業務、コンサル等のカスタマイズサービスまで。カスタマーサポートがお客様のお問合せに一つ一つ丁寧に対応します。

solution to suity our need epidemiology pharma intelligence

一人ひとりのお客様に最適なソリューション

分析レポート単体の購入から法人単位の購読契約やコンサル案件まで。各お客様のニーズにしっかり向き合います。

ファーマインテリジェンスが提供するサービスブランド

Biomedtracker
DMHC
In Vivo
Meddevicetracker
Medtech-Insight
Medtrack
Pharma consulting
Pharmapremia
Pharmaprojects
Pink Sheet
RxScorecard
Scrip
Sitetrove
Trialtrove

メールサービスの最新記事

  • Biomedtracker

    Clinical Trials Industry Report

    By KNect365 17 Aug 2018

    Clinical trials are continually evolving, particularly in light of increasing pressures from new technologies and other disruptors. Trends ranging from artificial intelligence (AI) and mHealth to patient-centricity are challenging the industry to innovate against the backdrop of looming regulatory changes and shifting competitor landscapes resulting from M&A activity. In order to explore these trends, KNect365 Life Sciences recently conducted one of the biggest surveys of its kind across clinical trial professionals from within pharma, CROs, sites, service providers, academia and patient groups across the world to look beyond the hype.

    Topic clinical-trials clinical-trial-optimization

  • Pharma Consulting

    Changing the future of data

    17 Aug 2018

    With fewer successful drug launches in the market and expiring patents, competitive intelligence and commercial R&D decision makers are hard-pressed to make sound forecasting and planning decisions based on highly reliable data analysis. That’s a big challenge because, even with access to big data from many sources, the tasks associated with collecting, organizing and mapping data sets is time-consuming, costly and labour-intensive. As result, decision making takes longer and innovation suffers.

    Topic business-strategies company-analysis

  • Scrip:世界の医薬品産業ニュースサービス

    Amicus' Oral Fabry Drug Priced To Compete Against Traditional ERT

    17 Aug 2018

    FDA approved Galafold under accelerated approval, paving the way for the launch of the first oral therapy to treat a subset of patients with the rare condition Fabry disease. Amicus priced Galafold at $315,000 per year.

    Topic FDA

  • Scrip:世界の医薬品産業ニュースサービス

    Sensyne Health CEO Drayson Says IPO Will See AI Group To Profitability

    By sten-stovall 17 Aug 2018

    Flush with IPO funding, AI-focused healthcare technology group Sensyne Health will now ready additional products and find three more NHS trust partnerships. CEO Lord Drayson spoke to Scrip.

    Topic research business-strategies

  • Medtech Insight:世界の医療機器に特化したニュース配信

    QSR Author Kim Trautman Predicts What A Mash-Up Of FDA's Quality System Regulation And ISO 13485 Might Look Like

    17 Aug 2018

    US FDA will face high hurdles as it works to write a new rule that would merge the agency's Quality System Regulation with international quality systems standard ISO 13485. That's according to Kim Trautman, a longtime industry insider who wrote the QSR in the early to mid-1990s. "It’s a clear heavy lift from a regulatory policy perspective" that could take as long as five years to complete, she says. In the meantime, Trautman offers some insight into what device-makers might see in a new hybrid quality systems regulation from FDA. She addresses everything from corrective and preventive action (CAPA) to labeling, and complaint handling to risk management – and more.

    Topic fda

  • Medtech Insight:世界の医療機器に特化したニュース配信

    Pre-Certs, Test Groups And More: US FDA Outlines Possible New Dx Paradigm

    17 Aug 2018

    The agency has responded to a draft diagnostics reform bill in Congress with proposed reforms that diverge some ways from the proposed legislation, but stick with the underlying goal of completely remaking how lab tests, including test kits and lab-developed tests, are regulated. The agency has put forward a proposal to establish a pre-certification process for test developers, divide most tests into high- or low-risk categories (but exempt many from pre-market review) and remove the concept of substantial equivalence.

    Topic fda

  • Rose Sheet:化粧品とサプリメントに関する規制ニュース

    GC3 Announces Preservative Challenge Winners

    17 Aug 2018

    Avisco, a biotech startup focused on the antimicrobial properties of the Inula viscosa plant, and IMD Natural Solutions, whose INS Glycolipid mushroom extract purportedly is “up to 80 times more effective than traditional preservatives,” are among winners named Aug. 6 by GC3.

    Topic biopharmaceutical

  • In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース

    True Innovation In Women's Health Hindered Because Conditions Are Not Fatal

    17 Aug 2018

    Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.

    Topic drug-approval drug-review

  • Biomedtracker

    Biomedtracker 2018 Early Outlook Report

    15 Aug 2018

    What's on the horizon for pharma in 2018? Find out with Biomedtracker's Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.

    Topic Drug development landscape

  • Biomedtracker

    Biomedtracker Q3 2018 Outlook Report Extract

    15 Aug 2018

    Download an extract of the data-rich resource: Biomedtracker’s Q3 2018 Outlook Report. This latest installment in Biomedtracker’s ongoing quarterly reports contains expected drug catalyst predictions, important clinical and regulatory milestones, and Large Impact catalysts for the upcoming quarter. 

    Topic Drug development landscape

  • Meddevicetracker

    Meddevicetracker Q3 2018 Outlook Report Extract

    14 Aug 2018

    In this report, we cover catalysts from 10 devices expected to occur in Q3 2018. These include important regulatory milestones and trial data across the cardiovascular, neurology,  and endocrine (including diabetes) spaces. Additionally, at the end of this report we have included a list of Large Impact catalysts through Q3 2018.

  • Scrip:世界の医薬品産業ニュースサービス

    Perrigo Looks To Spin Out Or Sell Off Rx Business, But Will Separating Generics Add Value?

    By Mandy Jackson 14 Aug 2018

    Perrigo previously saw value in keeping its prescription pharmaceuticals in-house, but now says it will sell off or spin out the topical generics to focus on its over-the-counter brands. Questions remain about whether the company's generics portfolio is valuable enough to stand alone or attract a buyer.

    Topic business-strategies drug-approval

  • Scrip:世界の医薬品産業ニュースサービス

    A Safe Harbor For Biotechs Ascletis BeiGene Mark Early Wins For HK Exchange

    By Jules Quartly 14 Aug 2018

    The market debuts of BeiGene and Ascletis on the new Hong Kong Stock Exchange’s Biotech section could further encourage other Chinese biotech companies as they seek to draw in a wider pool of investors and focus on the promising domestic sector.

    Topic Business strategies Company analysis

  • Pink Sheet:世界の薬事規制と承認審査に関するニュース

    US FDA’s Breakthrough And RMAT Designations: A Quick Guide

    By Bridget Silverman 14 Aug 2018

    Differences in eligibility and evidentiary criteria between the US FDA's two expedited regulatory programs are reflected in a new guide; metrics to date suggest comparable success rates for designation requests under the two programs. Our infographics aid in understanding the programs.

    Topic fda

  • In Vivo : 医薬品・医療機器業界の経営層を対象としたニュース

    Cancer's New Patient Demographic; Will Survivorship Change The Face Of Cancer Care?

    By William Looney 13 Aug 2018

    The 16 million survivors of cancer in the US today form a restless constituency with its own disparate set of interests – and by sheer weight of numbers is beginning to direct changes to medical practice that pose both risks and opportunity for biopharma.

    Topic cancer

関連する製品

trial trove pharma intelligence

Trialtrove

Key benefits:

  • 専門家による情報精査
  • 世界中の臨床試験情報を網羅
  • 標準治療に関する情報
pdpimage

Datamonitor Healthcare

Key benefits:

  • 市場機会を見極める
  • アンメットニーズを特定
  • データドリブンの意思決定
scrip pharma intelligence

Scrip:世界の医薬品産業ニュースサービス

Key benefits:

  • Scripジャーナリストチーム
  • Go beyond the news
  • Hear from news makers

最新のイベント情報

26 Aug 2018 , 09:30 CST

Switzerland

Industry conference

AMEE

05 Sep 2018

Massachusetts , USA

Industry conference

BioPharm America 2018

06 Sep 2018

Industry conference

IMAC 2018

Keep up to date